Home / Companies / News /  Invictus Oncology raises `10.5 crore from Navam Capital, Aarin Capital

Mumbai: Invictus Oncology Pvt. Ltd has raised 10.5 crore from investors Navam Capital and Aarin Capital in its first round of fund-raising.

The company is developing chemotherapy models that it says will be more effective and less toxic than the treatment now available.

Aarin Capital is led by Ranjan Pai, managing director and chief executive officer, Manipal Education, and T.V. Mohandas Pai, former human resources director at Infosys Ltd. The fund invests in companies offering innovative healthcare, life sciences and technology-based products or services.

Invictus said it will deploy the new financing to advance the development of platinum chemotherapies used in the treatment of several types of cancer, including lung, testicular, colorectal, and childhood cancers.

Invictus will also accelerate the pre-clinical development of its antibody-drug conjugate platform technology that uses a proprietary technology.

“We are designing next generation drugs that are more effective while dialing out such adverse side effects. India is a great place to pursue scientific innovation and commercialize cutting edge technologies," said Shiladitya Sengupta, co-founder of Invictus and assistant professor of medicine at Harvard Medical School.

“Invictus’ technology has the potential to transform cancer treatment. Invictus will challenge assumptions and change perceptions about India’s capacity to deliver product innovation," said Rajeev Mantri, executive director of Navam Capital.

Catch all the Corporate news and Updates on Live Mint. Download The Mint News App to get Daily Market Updates & Live Business News.
More Less

Recommended For You

Trending Stocks

Get alerts on WhatsApp
Set Preferences My ReadsWatchlistFeedbackRedeem a Gift CardLogout